Quarterly report pursuant to Section 13 or 15(d)

Note 11 - Segment Information (Tables)

v3.8.0.1
Note 11 - Segment Information (Tables)
 6 Months Ended
Dec. 31, 2017
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
   
Quarter Ended
    
Six M
onths Ended
  
   
December 31,
    
December 31,
  
   
2017
    
2016
    
2017
    
2016
  
Net sales:
                                
Biotechnology
    
101,411
      
85,953
     $
196,487
     $
172,740
  
Protein Platforms
    
29,388
      
21,548
      
54,028
      
41,121
  
Diagnostics
    
23,429
      
24,330
      
48,415
      
48,563
  
Intersegment
    
(75
)
    
(24
)
    
(164
)
    
(36
)
Consolidated net sales
    
154,153
      
131,807
     $
298,766
     $
262,388
  
O
perating income:
                                
Biotechnology
   $
46,210
     $
39,474
     $
90,813
     $
81,594
  
Protein Platforms
    
6,119
      
1,843
      
9,175
      
2,052
  
Diagnostics
    
3,777
      
5,801
      
9,606
      
12,104
  
Segment
operating income
   $
56,106
     $
47,118
     $
109,594
     $
96,110
  
Costs recognized on sale of acquired inventory
    
(264
)
    
(789
)
    
(582
)
    
(2,133
)
Amortization of acquisition related intangible assets
    
(11,296
)
    
(11,627
)
    
(22,675
)
    
(21,815
)
Acquisition related expenses
    
(13,150
)
    
(12,056
)
    
(22,683
)
    
(15,588
)
Stock based compensation
    
(5,044
)
    
(4,055
)
    
(8,839
)
    
(7,245
)
Corporate general, selling, and administrative
expenses
    
(2,204
)
    
(710
)
    
(4,636
)
    
(2,293
)
Consolidated operating
income
    
24,148
      
17,881
     $
50,179
     $
47,036